Compositions and methods for determining the replication capacity of a pathogenic virus
OwnerWei Huang, Mary T. Wrin +5inventors
InventorsWei Huang, Mary T. Wrin, Andrea Garmanik, Jeff Beauchaine, Jeannette M. Whitcomb, Christos J. Petropoulos, Neil T. Parkin
Life of this patent
Estimating the term…
Abstract
This invention relates to compositions and methods for determining the replication capacity of a non-nucleoside reverse transcriptase inhibitor resistant virus. The compositions and methods are useful for identifying effective drug regimens for the treatment of viral infections, and identifying and determining the biological effectiveness of potential therapeutic compounds.
Claims20
A method for determining whether a human immunodeficiency virus type 1 (“HIV-1”) has an increased likelihood of having an impaired replication capacity, comprising:
- detecting whether the reverse transcriptase encoded by said HIV-1 exhibits the presence or absence of a mutation associated with impaired replication capacity at amino acid position 98, 100, 101, 103, 106, 108, 179, 181, 188, 190, 225 or 236 of the amino acid sequence of said reverse transcriptase, wherein the presence of said mutation indicates that the HIV-1 has an increased likelihood of having impaired replication capacity, with the proviso that said mutation is not P236L.
A method for determining whether a subject has an HIV-1 with an increased likelihood of having an impaired replication capacity, comprising:
- detecting whether the reverse transcriptase encoded by said HIV-1 exhibits the presence or absence of a mutation associated with impaired replication capacity at amino acid position 98, 100, 101, 103, 106, 108, 179, 181, 188, 190, 225 or 236 of the amino acid sequence of said reverse transcriptase, wherein the presence of said mutation indicates that the HIV-1 has an increased likelihood of having impaired replication capacity, with the proviso that said mutation is not P236L.
An isolated oligonucleotide between about 10 and about 40 nucleotides long encoding a portion of a HIV reverse transcriptase in a HIV-1 that comprises at least one mutation at amino acid position 98, 100, 101, 103, 106, 108, 179, 181, 188, 190, 225 or 236 of an amino acid sequence of said reverse transcriptase in said HIV-1, wherein the mutation is associated with reduced susceptibility to a protease inhibitor, with the proviso that said mutation is not P236L.
Dependencies are inferred from the claim text.